Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for CS43158 Tablets
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for CS43158 Tablets
Filed with SSE · Stock code 688321 · · 2 pages · Chinese
Summary by 6ix AI
Investors are cautioned that while the approval is a positive step, the clinical trial process is lengthy and uncertain, which may not significantly impact the company's short-term performance.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Release
Shenzhen Chipscreen Biosciences Co. Ltd. on 6ix
Story so far
Earlier from Shenzhen Chipscreen Biosciences
- (688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Conversion Results of Convertible Bonds and Share Changes
- Announcement on Listing and Trading of Restricted Shares from 2024 Private Placement of Shares
- Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Voluntary Disclosure Regarding Acceptance of Clinical Trial Application for NW001
Later from Shenzhen Chipscreen Biosciences
- (688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Acceptance of Clinical Trial Application for CS23546 Tablets
- (688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Receipt of the Drug Clinical Trial Approval Notice for NW001
- (688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
- (688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Signing of Project Cooperative Development Agreement and Related Party Transactions
Follow Shenzhen Chipscreen Biosciences into a list and get an email when it puts out news.
Follow Shenzhen Chipscreen Biosciences